Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered into a strategic partnership with Wecomput Technology Co., Ltd, a prominent computational contract research organization (CRO) in China with a global footprint. The collaboration aims to harness the power of artificial intelligence (AI) to enhance drug development capabilities. While the financial details of the agreement were not disclosed, the partnership signifies a significant step towards integrating advanced AI technologies into the pharmaceutical industry.
Innovent Academy, the core research and development (R&D) arm of Innovent, which has been actively engaged in AI-driven drug development, will adopt Wecomput’s WeMol platform. This integration is expected to enhance Innovent’s computational platform, thereby accelerating the drug development process. The collaboration is poised to streamline R&D efforts and potentially expedite the delivery of innovative therapies to market.- Flcube.com
